Similarly, the notably lower accuracy of plasma NTA-tau discriminating Aβ-PET compared with tau-PET indicates that the abnormal emergence of this biomarker across the AD continuum is closer in time to tau-PET crossing the positivity threshold, thus providing another indication of its late-stage nature. Here, MAPT is linked to Alzheimer disease.